Lenalidomide, an immunomodulatory drug (IMID), with activity in B-cell non-Hodgkin's lymphoma (NHL), targets this circuit by downregulating IRF4/SBIP, increasing toxic IFNβ secretion, and decreasing NF-κB activity [17, 38]. This evidence concerns the gene NFKB1 and non-Hodgkin lymphoma.